TY - JOUR
T1 - Differential gene expression in ovarian carcinoma
T2 - Identification of potential biomarkers
AU - Hibbs, Kathleen
AU - Skubitz, Keith M.
AU - Pambuccian, Stefan E.
AU - Casey, Rachael C.
AU - Burleson, Kathryn M.
AU - Oegema, Theodore R.
AU - Thiele, Jeannine J.
AU - Grindle, Suzanne M.
AU - Bliss, Robin L.
AU - Skubitz, Amy P.N.
N1 - Funding Information:
Supported by grants from the Department of the Army ( DA/DAMD17-99-1-9564 ), the National Institutes of Health/National Cancer Institute ( CA0913825 ), the Minnesota Medical Foundation, and the Minnesota Ovarian Cancer Alliance.
PY - 2004/8
Y1 - 2004/8
N2 - Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing ∼12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the β8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX α2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein Al. Statistical analyses showed that the β8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.
AB - Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing ∼12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the β8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX α2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein Al. Statistical analyses showed that the β8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=3242813597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242813597&partnerID=8YFLogxK
U2 - 10.1016/S0002-9440(10)63306-8
DO - 10.1016/S0002-9440(10)63306-8
M3 - Article
C2 - 15277215
AN - SCOPUS:3242813597
SN - 0002-9440
VL - 165
SP - 397
EP - 414
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 2
ER -
